BioMarin Pharmaceutical Inc. (BMRN) Financial Statements (2024 and earlier)

Company Profile

Business Address 105 DIGITAL DRIVE
NOVATO, CA 94949
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in millions)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,2921,0141,0657541,0841,396
Cash and cash equivalents725587649437494598
Short-term investments567427416316590798
Receivables461373448377343261
Inventory, net of allowances, customer advances and progress billings894777699680531476
Inventory894777699680531476
Other current assets1051101301319874
Total current assets:2,7512,2742,3421,9422,0562,207
Noncurrent Assets
Property, plant and equipment1,0731,0351,0321,011949897
Long-term investments and receivables334508285412236386
Long-term investments334508285412236386
Intangible assets, net (including goodwill)535585613654689715
Goodwill196196196197197197
Intangible assets, net (excluding goodwill)339389417457492518
Deferred income tax assets1,5051,4491,432549
Other noncurrent assets1761521421223730
Other undisclosed noncurrent assets     461399
Total noncurrent assets:3,6243,7293,5062,7482,3712,426
TOTAL ASSETS:6,3756,0035,8484,6904,4274,633
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:573492493571437402
Taxes payable2108810
Employee-related liabilities204165192150141
Accrued liabilities2371517316355
Other undisclosed accounts payable and accrued liabilities336270301339216196
Debt   362 361
Business combination, contingent consideration, liability 1648  8654
Total current liabilities:589540493933523817
Noncurrent Liabilities
Long-term debt and lease obligation1,0831,0791,075486830814
Long-term debt, excluding current maturities1,0831,0791,075486830814
Liabilities, other than long-term debt100114174149106194
Other liabilities10099114985959
Business combination, contingent consideration, liability  15605147135
Total noncurrent liabilities:1,1831,1931,2496359361,008
Total liabilities:1,7721,7331,7421,5681,4591,824
Equity
Equity, attributable to parent, including:4,6034,2714,1063,1222,9682,809
Common stock000000
Additional paid in capital5,4055,1924,9934,8334,6704,483
Accumulated other comprehensive income (loss)(4)14(16)205(23)
Accumulated deficit(789)(926)(862)(1,721)(1,694)(1,638)
Other undisclosed equity, attributable to parent(9)(10)(10)(10)(13)(14)
Total equity:4,6034,2714,1063,1222,9682,809
TOTAL LIABILITIES AND EQUITY:6,3756,0035,8484,6904,4274,633

Income Statement (P&L) ($ in millions)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues2,0961,8461,8601,7041,4911,314
Revenue, net1,314
Cost of revenue(484)(471)(524)(359)(315)(242)
Gross profit:1,6121,3761,3361,3451,1761,072
Operating expenses(1,396)(1,388)(1,306)(1,371)(1,251)(1,040)
Other undisclosed operating loss(67)(70)(67)(74)(49)(46)
Operating income (loss):150(82)(37)(100)(124)(15)
Nonoperating income1810922419
Investment income, nonoperating181017232315
Gain (loss), foreign currency transaction, before tax   (8)(1)18(6)
Interest and debt expense(16)(15)(29)(23)(44)(43)
Income (loss) from continuing operations before equity method investments, income taxes:152(87)(57)(102)(127)(49)
Loss from equity method investments   (0)(1)(1)(1)
Other undisclosed income (loss) from continuing operations before income taxes(2)12158(16)14
Income (loss) from continuing operations before income taxes:150(75)(42)(95)(143)(36)
Income tax expense (benefit)(8)119017165(81)
Income (loss) from continuing operations:142(64)859(24)(77)(117)
Income (loss) before gain (loss) on sale of properties:(64)859(24)(77)(117)
Net income (loss) available to common stockholders, basic:142(64)859(24)(77)(117)
Interest on convertible debt  8   
Other undisclosed net loss available to common stockholders, diluted    (1) 
Net income (loss) available to common stockholders, diluted:142(64)867(24)(78)(117)

Comprehensive Income ($ in millions)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net income (loss):142(64)859(24)(77)(117)
Other comprehensive income (loss) (18)31(36)1529(36)
Other undisclosed comprehensive loss      
Comprehensive income (loss):123(34)823(9)(48)(153)
Other undisclosed comprehensive loss, net of tax, attributable to parent      
Comprehensive income (loss), net of tax, attributable to parent:123(34)823(9)(48)(153)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: